Insider · CIK 0002064881
John Saewook Kauh M.D.
Files at TVRD (Tvardi Therapeutics, Inc.). First filing -, latest -.
John Saewook Kauh M.D. files SEC Form 4 as officer at TVRD (Tvardi Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; John Saewook Kauh M.D. has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 29, 2026 | TVRD Tvardi Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Feb 2, 2026 |
| Dec 16, 2025 | TVRD Tvardi Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Dec 18, 2025 |
| Apr 17, 2025 | TVRD Tvardi Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +36,210 | $0.00 | $0 | 36,210 | Apr 21, 2025 |
| Apr 15, 2025 | TVRD Tvardi Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +74,049 | - | - | 74,049 | Apr 17, 2025 |
Questions about John Saewook Kauh M.D.
Answered from the filings on this page, as of the latest one.
Is John Saewook Kauh M.D. buying or selling?
John Saewook Kauh M.D. has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did John Saewook Kauh M.D.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Saewook Kauh M.D. has 0.
Where does John Saewook Kauh M.D. file Form 4?
John Saewook Kauh M.D. has filed Form 4 at TVRD (Tvardi Therapeutics, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.